Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Adding the experimental oral therapy voclosporin to standard treatment is safe, and its use more than doubles complete kidney responses in people with lupus nephritis, results from the Phase 3 ... Read more
More stringent thresholds in the Cutaneous Lupus Activity and Severity Index (CLASI), a common tool to assess disease progression and treatment response in cutaneous lupus erythematosus (CLE), can better ... Read more
While people with systemic lupus erythematous lupus (SLE) are experiencing fewer eye complications directly linked to the disease, treatment-induced eye toxicity and age-related eye complications are becoming more frequent, ... Read more
Hardening of the kidney arteries, a condition called renal arteriosclerosis, is detected two decades earlier in people with lupus nephritis compared with healthy individuals, a study shows. The study, ... Read more
More than 40% of systemic lupus erythematosus (SLE) patients do not comply with hydroxychloroquine (HCQ) therapy, even among people who have insurance coverage, low copayments, and availability of high ... Read more
Apellis Pharmaceuticals has decided to stop the development of an experimental therapy known as APL-2 for lupus nephritis and primary membranous nephropathy after the completion of an ongoing Phase ... Read more